BACKGROUND: We report here the logistic modeling of the epidemiologic differences between a diagnostic population and a screening population recruited for the study of optical technologies for cervical cancer detection. OBJECTIVES: The goal of this analysis was to determine if there were differences in the sociodemographic or clinical factors between subjects recruited to our diagnostic and screening trials. METHODS: Epidemiologic data were obtained from a risk factor interview as a component of a multicenter Phase II clinical trial that used fluorescence and reflectance point spectroscopy to diagnose cervical disease. Participants with recent or past abnormal findings on a Papanicolaou smear were grouped into the diagnostic (high-risk) population, whereas those with a history of normal findings on Papanicolaou smears and no cervical treatments were grouped into the screening (low-risk) population. RESULTS: Our model revealed that nonwhite race, higher than a high school education, and peri- and postmenopausal status were associated with the screening population. A history of genital infections, current oral contraceptive use, human papillomavirus positivity (by Hybrid Capture II and consensus polymerase chain reaction), and worst histological diagnosis at clinic visit were important predictors of being in the diagnostic group. CONCLUSIONS: We were successful in recruiting 2 distinctive populations and anticipate being able to use these results to more correctly classify women at higher risk for cervical lesions in our future studies of optical spectroscopy.
BACKGROUND: We report here the logistic modeling of the epidemiologic differences between a diagnostic population and a screening population recruited for the study of optical technologies for cervical cancer detection. OBJECTIVES: The goal of this analysis was to determine if there were differences in the sociodemographic or clinical factors between subjects recruited to our diagnostic and screening trials. METHODS: Epidemiologic data were obtained from a risk factor interview as a component of a multicenter Phase II clinical trial that used fluorescence and reflectance point spectroscopy to diagnose cervical disease. Participants with recent or past abnormal findings on a Papanicolaou smear were grouped into the diagnostic (high-risk) population, whereas those with a history of normal findings on Papanicolaou smears and no cervical treatments were grouped into the screening (low-risk) population. RESULTS: Our model revealed that nonwhite race, higher than a high school education, and peri- and postmenopausal status were associated with the screening population. A history of genital infections, current oral contraceptive use, human papillomavirus positivity (by Hybrid Capture II and consensus polymerase chain reaction), and worst histological diagnosis at clinic visit were important predictors of being in the diagnostic group. CONCLUSIONS: We were successful in recruiting 2 distinctive populations and anticipate being able to use these results to more correctly classify women at higher risk for cervical lesions in our future studies of optical spectroscopy.
Authors: J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz Journal: J Pathol Date: 1999-09 Impact factor: 7.996
Authors: Anais Malpica; Jasenka P Matisic; Dirk Van Niekirk; Christopher P Crum; Gregg A Staerkel; Jose-Miguel Yamal; Martial H Guillaud; Dennis D Cox; Edward Neely Atkinson; Karen Adler-Storthz; Neal M Poulin; Calum A Macaulay; Michele Follen Journal: Gynecol Oncol Date: 2005-09-23 Impact factor: 5.482
Authors: Victor Moreno; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Jan M M Walboomers; Rolando Herrero; Silvia Franceschi Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: L A Brinton; W C Reeves; M M Brenes; R Herrero; R C de Britton; E Gaitan; F Tenorio; M Garcia; W E Rawls Journal: Int J Epidemiol Date: 1990-03 Impact factor: 7.196
Authors: L Kjellberg; G Hallmans; A M Ahren; R Johansson; F Bergman; G Wadell; T Angström; J Dillner Journal: Br J Cancer Date: 2000-04 Impact factor: 7.640
Authors: J R Montealegre; E C Peckham-Gregory; D Marquez-Do; L Dillon; M Guillaud; K Adler-Storthz; M Follen; M E Scheurer Journal: Gynecol Oncol Date: 2017-12-21 Impact factor: 5.482
Authors: Scott B Cantor; Jose-Miguel Yamal; Martial Guillaud; Dennis D Cox; E Neely Atkinson; John L Benedet; Dianne Miller; Thomas Ehlen; Jasenka Matisic; Dirk van Niekerk; Monique Bertrand; Andrea Milbourne; Helen Rhodes; Anais Malpica; Gregg Staerkel; Shahla Nader-Eftekhari; Karen Adler-Storthz; Michael E Scheurer; Karen Basen-Engquist; Eileen Shinn; Loyd A West; Anne-Therese Vlastos; Xia Tao; J Robert Beck; Calum Macaulay; Michele Follen Journal: Int J Cancer Date: 2010-11-09 Impact factor: 7.396